CN104547929A - 一种治疗中风后遗症的中药及制备方法 - Google Patents
一种治疗中风后遗症的中药及制备方法 Download PDFInfo
- Publication number
- CN104547929A CN104547929A CN201510007910.7A CN201510007910A CN104547929A CN 104547929 A CN104547929 A CN 104547929A CN 201510007910 A CN201510007910 A CN 201510007910A CN 104547929 A CN104547929 A CN 104547929A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- rhizoma curcumae
- hirudo
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 208000006011 Stroke Diseases 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 241000545744 Hirudinea Species 0.000 claims abstract description 5
- 241000237903 Hirudo Species 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 15
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007963 capsule composition Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 5
- 241000500851 Poecilobdella manillensis Species 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 210000001215 vagina Anatomy 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000009495 sugar coating Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 14
- 208000007536 Thrombosis Diseases 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 10
- 230000004087 circulation Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000002490 cerebral effect Effects 0.000 abstract description 7
- 206010019468 Hemiplegia Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 14
- 206010008118 cerebral infarction Diseases 0.000 description 9
- 102000007625 Hirudins Human genes 0.000 description 7
- 108010007267 Hirudins Proteins 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- 235000012754 curcumin Nutrition 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940006607 hirudin Drugs 0.000 description 7
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010018873 Haemoconcentration Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 201000008247 brain infarction Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001769 paralizing effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000146385 Hirudo nipponia Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000371027 Poecilobdella Species 0.000 description 1
- 241000500853 Poecilobdella hubeiensis Species 0.000 description 1
- 241000500852 Poecilobdella javanica Species 0.000 description 1
- 241001665183 Poecilobdella nanjingensis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- -1 yellow acid aldehydes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗中风后遗症的中药及制备方法,属心脑血管疾病中药制备技术领域。其特点是:治疗中风后遗症的中药由刺五加、水蛭、莪术三种中药材组成,针对中风病人气血两虚,血流不畅的病因,采用中医补气、行气、活血辩证施治,通过对刺五加、水蛭和莪术三种中药原料进行有效成分提取、低温超微粉碎、冷冻干燥的特殊制备工艺,最大限度的保存了药材的活性成分,使有效成分能被患者充分吸收,服用安全可靠,疗效确切。治疗针对性强,对扩张血管,降低血液粘稠度,改善脑循环作用有显效;对抑制血栓、行气破血、消积止痛作用明显。解决了现有技术对心脑血管病导致的中风偏瘫的针对治疗性不强,致使治疗效果差的问题。
Description
技术领域
本发明涉及一种治疗中风后遗症的中药及制备方法,属心脑血管疾病中药制备技术领域。
背景技术
心脑血管病是最常见的导致衰老和致死的疾病。中医学认为,气血是构成人体和维持人体生命活动最基本的物质,临床无论是血塞型还是出血型中风患者,都会表现出气虚血瘀,血流不畅,络脉痹阻,进而出现四肢麻木、偏瘫等症状,致死率极高;因此,中医对心脑血管病的主要治疗方法是益气化瘀,目前使用的益气化瘀组方有很多种,但针对心脑血管病导致的偏瘫的治疗效果差,亟待改进完善。
发明内容
本发明的目的在于,提供一种针对治疗性强,扩张血管,降低血液粘稠度,改善脑循环作用好;抑制血栓、行气破血、消积止痛作用明显;解决现有技术对心脑血管病导致的偏瘫的治疗针对性不强,致使治疗效果差等问题的治疗中风后遗症的中药及制备方法。
本发明是通过如下的技术方案来实现上述目的的
一种治疗中风后遗症的中药,其特征在于:它由下述重量份的原料组成:
刺五加6~2份,水蛭1~3份,莪术4~1份;
所述的水蛭为日本医蛭、丽医蛭、菲牛蛭、棒纹牛蛭、湖北牛蛭或南京牛蛭中的一种;
所述的莪术可由姜黄代替;
该治疗中风后遗症的中药的制备方法如下:
第一步:提取有效成分
(1)、刺五加的提取:选取中药刺五加的茎及根皮,按上述配方称取整数倍的刺五加,超微粉碎,加入12倍重量比、纯度为75%的乙醇,24小时回流提取三次,收集提取液,浓缩干燥,提取物称重,待用;
(2)、莪术的提取:莪术选用中药莪术的根茎,按上述配方称取整数倍的莪术,超微粉碎,加9倍水搅拌,回流蒸馏6小时,收集莪术油;残渣过滤,固体物中加入5倍、纯度为75% 的乙醇搅拌提取三次,收集提取液,浓缩烘干称重,待用;
(3)、水蛭粉的准备:选用吸血蚂蟥,将活体水蛭冰冻,也可用液氮速冻;称取本配方整数倍的水蛭活体冻品在4℃温度下超微粉碎,浆冻干,再粉碎后测试活力后称重,待用;
第二步:混合
将上述三种药材的提取物混合,莪术油均匀喷洒入混合物中,放入超微粉碎机中粉碎、混合均匀;
第三步:灭菌
将混匀后的提取物粉末在Co60射线下照射1分钟;检测细菌总数,检测合格,待用;
第四步:制作成品
将灭菌后的粉末按以下方式制成胶囊剂型或片剂型成品;
胶囊剂型:将灭菌后的粉末装入胶囊成型机中,胶囊采用容量为0.25克的1号肠溶胶囊,每粒净重0.25克,挑拣出破损产品,将合格胶囊颗粒制作成胶囊板,装盒或装瓶;
片剂型:严格按国标药剂片制作要求加入规定量的、经过灭菌处理的医用淀粉;压片,包糖衣,每片重量1g~2g,每克含上述粉末0.25g;
第五步:包装后入库,室温保存。
本发明与现有技术相比的有益效果在于
一种治疗中风后遗症的中药配方及制备方法,它由刺五加、水蛭、莪术三味中药的提取物组成,通过本发明五步制备步骤制作而成。三种药材均有活血化瘀功能,完全符合中医辩证治疗的理论。通过刺五加补气,莪术行气,水蛭活血,可明显扩张脑血管,降低血液浓度,抑制血小板聚集,改善脑循环,减轻脑缺血继发性损害,降低血液黏稠度和降低血脂,加速血栓溶解,促成抗血栓的形成;能使脑血块内或内皮下的凝血酶灭活,明显抑制血栓形成,对已形成的血栓具有好的溶栓作用。同时改善受损的神经功能,对脑缺血再灌注损伤起保护作用。治疗针对性强,补气活血,化瘀通络效果好;抑制血栓、行气破血作用明显;服用安全可靠,疗效确切。解决了现有技术对心脑血管病导致偏瘫的治疗针对性不强,致使治疗效果差的问题。
具体实施方式
下面对本发明作进一步详细描述:
该治疗中风后遗症的中药由下述重量份的原料组成:
刺五加6~2份,水蛭1~3份,莪术4~1份;
所述的水蛭为日本医蛭、丽医蛭、菲牛蛭、棒纹牛蛭、湖北牛蛭或南京牛蛭中的一种;
所述的莪术可由姜黄代替;
该治疗中风后遗症的中药的制备方法如下:
第一步:提取有效成分
(1)、刺五加的提取:选取中药刺五加的茎及根皮,按上述配方称取整数倍的刺五加,超微粉碎,加入12倍重量比、纯度为75%的乙醇,24小时回流提取三次,收集提取液,浓缩干燥,提取物称重,待用;
(2)、莪术的提取:莪术选用中药莪术的根茎,按上述配方称取整数倍的莪术,超微粉碎,加9倍水搅拌,回流蒸馏6小时,收集莪术油;残渣过滤,固体物中加入5倍、纯度为75% 的乙醇搅拌提取三次,收集提取液,浓缩烘干称重,待用;
(3)、水蛭粉的准备:选用吸血蚂蟥,将活体水蛭冰冻,也可用液氮速冻;称取本配方整数倍的水蛭活体冻品在4℃温度下超微粉碎,浆冻干,再粉碎后测试活力后称重,待用;
第二步:混合
将上述三种药材的提取物混合,莪术油均匀喷洒入混合物中,放入超微粉碎机中粉碎、混合均匀;
第三步:灭菌
将混匀后的提取物粉末在Co60射线下照射1分钟;检测细菌总数,检测合格,待用;
第四步:制作成品
将灭菌后的粉末按以下方式制成胶囊剂型或片剂型成品;
胶囊剂型:将灭菌后的粉末装入胶囊成型机中,胶囊采用容量为0.25克的1号肠溶胶囊,每粒净重0.25克,挑拣出破损产品,将合格胶囊颗粒制作成胶囊板,装盒或装瓶;
片剂型:严格按国标药剂片制作要求加入规定量的、经过灭菌处理的医用淀粉;压片,包糖衣,每片重量1g~2g,每克含上述粉末0.25g;
第五步:包装后入库,室温保存。
本发明的优选方案为:
刺五加4-2份,水蛭1-2份,莪术3-1份。
本发明的最佳方案为:
刺五加3份,水蛭1份,莪术2份。
本发明的刺五加为中药刺五加的茎和根皮,莪术为姜科植物的蓬莪术或温莪术、广西莪术、姜黄。
所述的水蛭为日本医蛭(Hirudo nipponia Whitman)、丽医蛭(Hirudo pulchra Song)、菲牛蛭(Poecilobdella manllillensis)、棒纹牛蛭(Poecilobdella javanica)、湖北牛蛭(Poecilobdella hubeiensis Yang)或南京牛蛭(Poecilobdella nanjingensis sp.nov.)中的一种。
本发明是基于祖国中医学对心脑血管疾病发病机理的研究和治疗原则,参考现代中医药理论研究的科研成果,按中医理论组方,打破传统用药禁忌,采用有效成分清楚、药理明确的刺五加、水蛭、莪术三味中药材合理组方而成。分别提取刺五加和莪术的有效成分,水蛭采用吸血水蛭,对水蛭进行液氮速冻、超微粉碎、冷冻干燥处理,最大限度的保存了水蛭素的活性及其他有效成分活性,能使药剂中所含有效成分让病人充分吸收,大大提高了中风患者的治疗效果。
本发明上述的原料组份中,每组份原料药的药性特点及功效如下:
刺五加是五加科植物刺五加的干燥根及根茎或茎;其味辛、微苦,性温,归脾、肾、心经。益气健脾,补肾安神。所含苷类与人参根中的皂苷具有相似的生理活性,医学上被称之为“适应原”样药物。
该治疗中风后遗症的中药及制备方法,治疗中风后遗症的中药由刺五加、水蛭、莪术三味中药的提取物组成,配方中的刺五加为君药,大量临床病例观察报导表明,用刺五加注射液治疗脑梗死患者,可明显扩张脑血管,降低血液浓度,抑制血小板聚集,改善脑循环,减轻脑缺血后的继发性损害。同时具有降低血液黏稠度和降低血脂的作用,加速血栓溶解,快速促成抗血栓的形成。
水蛭又名蚂蟥,中医研究表明水蛭为破血逐瘀之品。本发明中水蛭为臣药,日本医蛭、丽医蛭、菲牛蛭、棒纹牛蛭、湖北牛蛭或南京牛蛭的唾液含有有效成分水蛭素,对凝血酶有高亲和性,可与凝血酶形成极稳定的复合物,在低浓度下即有抑制凝血酶活性的作用,是天然的凝血酶特效抑制剂;水蛭素亦具有类似肝素样作用,但与肝素不同,它不需抗凝血酶Ⅲ作为辅助因子,不会被肝素蛋白灭活,可使脑血块内或内皮下的凝血酶灭活,抑制凝血酶对血小板的作用。据医学实验报道,凝血酶诱发的血液凝固是血管血栓形成的主要机理,水蛭素同样可明显抑制血栓形成,并对已形成的血栓具有好的溶栓作用,由于水蛭素可直接靶向凝血酶,能有效地防止纤维蛋白和血细胞结合形成血凝块,因此可防止各类血栓的形成及延伸。水蛭素可增加脑血流量,促进脑血肿的吸收,减轻血肿周围炎性反应性水肿,缓解颅内高压,改善局部血液循环,减少脑梗死面积,保护脑组织。
莪术具有行气破血、消积止痛的功效。本发明中为辅佐药。《医学衷中参西录》:“莪术:味微苦,气微香,亦微有辛意。性皆微温,为化瘀血之要药。”“若治瘀血积久过坚硬者,原非数剂所能愈,必以补药佐之,方能久服无弊。或用黄芪六钱,三棱、莪术各三钱,或减黄芪三钱,加野台参三钱,其补破之力皆可相敌,不但气血不受伤损,瘀血之化亦较速,盖人之气血壮旺,愈能驾驭药力以胜病也。” 莪术含姜黄素。姜黄素是从姜科植物中提取的一种黄色酸性酚类物质,大量研究证明,姜黄素具有抗氧化、抗炎、清除自由基、抗微生物以及保护心脑血管系统等药理作用。采用姜黄素治疗心脑血管疾病,是中医新药的研究领域,在脑保护及治疗脑血管病方面具有良好的应用前景。姜黄素可通过上调Bcl-2蛋白下调Bax蛋白表达,减少脑缺血再灌注后神经细胞凋亡,从而改善受损的神经功能,对脑缺血再灌注损伤起保护作用。研究表明,姜黄素对脑缺血再灌注损伤的保护机制包括影响超氧化物歧化酶(SOD)和谷胱甘肽过氧化酶(GPX)、丙二醛(MDA)、黄嘌呤脱氢酶/黄嘌呤氧化酶(XD/XO)、一氧化氮((NO)、脑组织钙和肿瘤坏死因子的含量;动物实验研究表明,姜黄素能降低脑梗死面积,对血管内皮的保护作用机制是通过抑制细胞间黏附分子一1 (ICAM-1)、血管细胞粘附分子一1(VCAM-1)和P-选择素的表达。
刺五加、水蛭、莪术三味中药制成配方,补气活血,化瘀通络,十分适合脑血管病中风患者治疗使用。
实施例:
以称取12kg刺五加皮、8kg莪术和4kg日本医蛭为原料进行胶囊剂型制备,其制备步骤如下:
第一步、提取有效成分
1、 刺五加的提取:
将12kg刺五加皮超微粉碎,加入12倍重量比的75%的乙醇,24小时回流提取三次,收集提取液,浓缩干燥,得提取物840g;待用;
2、 莪术的提取:
将8kg莪术超微粉碎,加9倍水搅拌,回流蒸馏6小时,收集莪术油,得80g。残渣过滤,固体物中加入5倍75% 的乙醇搅拌提取三次,收集提取液,浓缩烘干得12g莪术油,待用。
3、水蛭粉的准备:
将4kg日本医蛭用液氮速冻后,于4℃温度下超微粉碎,将浆冻干,再粉碎后得3.8kg水蛭粉,测活力为每克201A-TU/g。
第二步、混合
将上述三种药材提取物混合,莪术油均匀喷洒入混合物中,放入超微粉碎机中粉碎、混合均匀,得混合物4732g。
第三步、灭菌
将混匀后的混合物粉末在Co60射线下照射1分钟;检测细菌总数合格,待用。
第四步、制作成品
胶囊剂型:将灭菌后的混合物粉末装入胶囊成型机中,胶囊采用容量为0.25克的1号肠溶胶囊,每粒净重0.25克,装入后将破损的产品挑出,然后制作成胶囊板或瓶装产品,共得18500颗成品,报废残次品420颗;合格产品每粒含水蛭素30/A-TU。
第五步、包装后入库,室温保存。
该产品通过公安县中医院临床检验,使用患者共20人,显效16人,占80%;其中基本治愈10人,有效3人,效果不明显1人;总有效率为95%。
Claims (3)
1.一种治疗中风后遗症的中药,其特征在于:它由下述重量份的原料组成:
刺五加6~2份, 水蛭1~3份, 莪术4~1份;
该治疗中风后遗症的中药的制备方法如下:
第一步:提取有效成分
(1)、刺五加的提取:选取中药刺五加的茎及根皮,按上述配方称取整数倍的刺五加,超微粉碎,加入12倍重量比、纯度为75%的乙醇,24小时回流提取三次,收集提取液,浓缩干燥,提取物称重,待用;
(2)、莪术的提取:莪术选用中药莪术的根茎,按上述配方称取整数倍的莪术,超微粉碎,加9倍水搅拌,回流蒸馏6小时,收集莪术油;残渣过滤,固体物中加入5倍、纯度为75% 的乙醇搅拌提取三次,收集提取液,浓缩烘干称重,待用;
(3)、水蛭粉的准备:选用吸血蚂蟥,将活体水蛭冰冻,也可用液氮速冻;称取本配方整数倍的水蛭活体冻品在4℃温度下超微粉碎,浆冻干,再粉碎后测试活力后称重,待用;
第二步:混合
将上述三种药材的提取物混合,莪术油均匀喷洒入混合物中,放入超微粉碎机中粉碎、混合均匀;
第三步:灭菌
将混匀后的提取物粉末在Co60射线下照射1分钟;检测细菌总数,检测合格,待用;
第四步:制作成品
将灭菌后的粉末按以下方式制成胶囊剂型或片剂型成品;
胶囊剂型:将灭菌后的粉末装入胶囊成型机中,胶囊采用容量为0.25克的1号肠溶胶囊,每粒净重0.25克,挑拣出破损产品,将合格胶囊颗粒制作成胶囊板,装盒或装瓶;
片剂型:严格按国标药剂片制作要求加入规定量的、经过灭菌处理的医用淀粉;压片,包糖衣,每片重量1g~2g,每克含上述粉末0.25g;
第五步:包装后入库,室温保存。
2.根据权利要求1所述的一种治疗中风后遗症的中药,其特征在于:所述的水蛭为日本医蛭、丽医蛭、菲牛蛭、棒纹牛蛭、湖北牛蛭或南京牛蛭中的一种。
3.根据权利要求1所述的一种治疗中风后遗症的中药,其特征在于:
所述的莪术可由姜黄代替。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510007910.7A CN104547929B (zh) | 2015-01-08 | 2015-01-08 | 一种治疗中风后遗症的中药及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510007910.7A CN104547929B (zh) | 2015-01-08 | 2015-01-08 | 一种治疗中风后遗症的中药及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104547929A true CN104547929A (zh) | 2015-04-29 |
CN104547929B CN104547929B (zh) | 2017-12-19 |
Family
ID=53065700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510007910.7A Active CN104547929B (zh) | 2015-01-08 | 2015-01-08 | 一种治疗中风后遗症的中药及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104547929B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895341A (zh) * | 2006-06-30 | 2007-01-17 | 北京科锐多科技有限公司 | 一种治疗心脑血管疾病中药制剂 |
CN104189785A (zh) * | 2014-09-27 | 2014-12-10 | 田丽华 | 一种用于治疗心脑血管疾病的药物 |
-
2015
- 2015-01-08 CN CN201510007910.7A patent/CN104547929B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895341A (zh) * | 2006-06-30 | 2007-01-17 | 北京科锐多科技有限公司 | 一种治疗心脑血管疾病中药制剂 |
CN104189785A (zh) * | 2014-09-27 | 2014-12-10 | 田丽华 | 一种用于治疗心脑血管疾病的药物 |
Non-Patent Citations (5)
Title |
---|
包祖晓等: "缺血性中风运用益气活血药的规律探讨", 《中医药研究》 * |
张卫等: "中药水蛭品种考证及资源可持续利用发展探讨", 《中国中药杂志》 * |
李军德等主编: "《中国药用动物志》", 30 June 2013, 福建科学技术出版社 * |
李勇等: "中药祛瘀利脑片的制备工艺研究", 《中南药学》 * |
梁娟等: "蛭龙通络胶囊的制备质量研究与稳定性考察", 《中国药物与临床》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104547929B (zh) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091203B (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
KR102127706B1 (ko) | 복합 한방 생약 추출물을 포함하는 혈행 개선용 제제 | |
CN105663926A (zh) | 一种降尿酸植物酵素及其制备方法 | |
CN104757536A (zh) | 恰玛古保健品 | |
CN114177261A (zh) | 一种防治慢性病及抗癌保健的中草药配方 | |
CN104547929A (zh) | 一种治疗中风后遗症的中药及制备方法 | |
CN105687672A (zh) | 一种治疗乳腺炎及乳腺增生的中药组合物及其制备方法 | |
CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
CN105031170A (zh) | 一种保健足浴粉及其制备方法 | |
CN112494614A (zh) | 一种木瓜百药组合防治癌病的中药配方 | |
CN104887866A (zh) | 治疗痛风的中药方剂 | |
CN104645247B (zh) | 一种治疗肝豆状核变性的中药制剂及其制备方法 | |
CN104623057A (zh) | 一种治疗糖尿病足的药物组合物及其应用 | |
CN108324783A (zh) | 白归参灵冬甘治癌药 | |
CN105012642B (zh) | 一种活血化瘀,止血止痛的中药组合物的制备方法 | |
CN107375913A (zh) | 一种负载纳豆激酶的血栓通络药物及其制备方法 | |
CN108478706A (zh) | 一种保护心血管的组合物及其制备方法 | |
CN107661422B (zh) | 一种防治冠心病的中药组合物及其制备方法 | |
CN105853843A (zh) | 一种临床用小儿伤口护理的药物组合物及其制备方法 | |
CN111700999A (zh) | 一种治疗肺癌的药物组合物及其应用 | |
CN113713038A (zh) | 一种通下药物及其制备方法 | |
CN111956724A (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN110711241A (zh) | 一种固本扶正化瘀膏及其制备方法 | |
CN107583024A (zh) | 一种治疗湿疹的组合物 | |
CN106668307A (zh) | 回族中药五加食管抗癌片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Ruquan Inventor after: Gong Yuan Inventor before: Gong Yuan |
|
CB03 | Change of inventor or designer information |